BK

Babu Kamal Satairam Saroj

Director Director DIN 06435762
DIN 06435762 First appointment Nov 2012 Primary industry Healthcare
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Nov 2012
Shareholding value β€’β€’β€’β€’ Premium profile

About Babu Kamal Satairam Saroj

Data last updated:

Babu Kamal Satairam Saroj was a Director at Jnn Lifesciences Private Limited (2012–2013) and Additional Director at Sterling Cancer & Diabetic Institute & Research Center Private Limited (2013). The companies operate in Healthcare.

DIN 06435762
Primary Designation Director
Industry Healthcare
First Appointment 16 Nov 2012

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Jnn Lifesciences Private Limited U85100MH2011PTC212484
Director16 Nov 20122011Under Liquidation
Additional Director08 Jan 20132012Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Jnn Lifesciences Private Limited
Sterling Cancer & Diabetic Institute & Research Center Private Limited
Premium access

Shareholding and investment profile for Babu Kamal Satairam Saroj

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Babu Kamal Satairam Saroj

Babu Kamal Satairam Saroj was first appointed on 16 Nov 2012 as Director at Jnn Lifesciences Private Limited. The most recent appointment on record is 08 Jan 2013 at Sterling Cancer & Diabetic Institute & Research Center Private Limited.

Babu Kamal Satairam Saroj held 2 earlier board appointments: Jnn Lifesciences Private Limited (Director, 16 Nov 2012 to 05 Dec 2013); Sterling Cancer & Diabetic Institute & Research Center Private Limited (Additional Director, 08 Jan 2013 to 22 Jun 2013).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available